MacDougall Conan, Powell J Patrick, Johnson Christopher K, Edmond Michael B, Polk Ronald E
Department of Pharmacy, School of Pharmacy, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, VA 23298, USA.
Clin Infect Dis. 2005 Aug 15;41(4):435-40. doi: 10.1086/432056. Epub 2005 Jun 28.
Fluoroquinolones are widely prescribed in hospitals and the community. Previous studies have shown associations between fluoroquinolone use and isolation of fluoroquinolone-resistant Escherichia coli and methicillin-resistant Staphylococcus aureus (MRSA). We performed an ecologic-level study to determine whether variability in hospital percentages of fluoroquinolone-resistant E. coli and MRSA were associated with fluoroquinolone use in hospitals and their surrounding communities.
We measured fluoroquinolone use in 17 US hospitals and their surrounding communities in the year 2000. Data on fluoroquinolone use in hospitals was electronically extracted from billing data. Data on fluoroquinolone use in communities was obtained from IMS health data for all prescriptions filled in pharmacies within a 16-km radius of each hospital. We used hospital antibiograms to determine the percentage of isolates that were fluoroquinolone-resistant E. coli and MRSA, and we performed linear regression to determine the relationship between percentage of resistant isolates and fluoroquinolone use in hospitals and their surrounding communities.
There was a significant association between total fluoroquinolone use within hospitals and percentage of S. aureus isolates that were MRSA (r=0.77; P=.0003) and between total fluoroquinolone use in the community and percentage of E. coli isolates that were fluoroquinolone-resistant E. coli (r=0.68; P=.003). Population density within the 16-km radius also correlated with MRSA percentage (r=0.57; P=.015) and fluoroquinolone-resistant E. coli percentage (r=0.85; P=.002), but associations between total fluoroquinolone use and resistance remained significant after adjustment for population density.
In this ecologic analysis, we found associations between fluoroquinolone use in hospitals and methicillin resistance in S. aureus and between fluoroquinolone use in communities and fluoroquinolone resistance in E. coli in hospitals. Antimicrobial use in hospitals and communities may have different relative importance with regard to resistance in different pathogens encountered in hospitals.
氟喹诺酮类药物在医院和社区中被广泛使用。先前的研究表明,使用氟喹诺酮类药物与耐氟喹诺酮大肠杆菌及耐甲氧西林金黄色葡萄球菌(MRSA)的分离之间存在关联。我们进行了一项生态学水平的研究,以确定医院中耐氟喹诺酮大肠杆菌和MRSA百分比的变异性是否与医院及其周边社区使用氟喹诺酮类药物有关。
我们测定了2000年美国17家医院及其周边社区的氟喹诺酮类药物使用情况。医院中氟喹诺酮类药物使用的数据通过电子方式从计费数据中提取。社区中氟喹诺酮类药物使用的数据来自IMS健康数据,该数据涵盖了每家医院半径16公里范围内药房所配所有处方。我们使用医院抗菌谱来确定耐氟喹诺酮大肠杆菌和MRSA分离株的百分比,并进行线性回归以确定医院及其周边社区中耐药分离株百分比与氟喹诺酮类药物使用之间的关系。
医院内氟喹诺酮类药物总使用量与MRSA金黄色葡萄球菌分离株百分比之间存在显著关联(r = 0.77;P = 0.0003),社区中氟喹诺酮类药物总使用量与耐氟喹诺酮大肠杆菌大肠杆菌分离株百分比之间存在显著关联(r = 0.68;P = 0.003)。16公里半径内的人口密度也与MRSA百分比(r = 0.57;P = 0.015)和耐氟喹诺酮大肠杆菌百分比(r = 0.85;P = 0.002)相关,但在调整人口密度后,氟喹诺酮类药物总使用量与耐药性之间的关联仍然显著。
在这项生态学分析中,我们发现医院中使用氟喹诺酮类药物与金黄色葡萄球菌中的甲氧西林耐药性之间存在关联,以及社区中使用氟喹诺酮类药物与医院中大肠杆菌的氟喹诺酮耐药性之间存在关联。医院和社区中的抗菌药物使用在医院中遇到的不同病原体的耐药性方面可能具有不同的相对重要性。